Seek immediate medical help if any of the following symptoms occur:
Hughes RA, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD002063. Review. Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003 Sep. 23;61(6):736-40. Sharar E. Current therapeutic options in severe Guillain-Barre syndrome. Clin Neuropharmacol. 2006 Jan-Feb;29(1):45-51. Wiles CM, Brown P, Chapel H, et al. Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry. 2002 Apr;72(4):440-8. Review. Goetz, CG. Textbook of Clinical Neurology. 2nd ed. St. Louis, Mo: WB Saunders; 2003: 1085-1090.
|
|
Reviewer Info: Daniel Kantor, M.D., Director of the Comprehensive MS Center, Neuroscience Institute, University of Florida Health Science Center, Jacksonville, FL. Review provided by VeriMed Healthcare Network.; ADAM Health Illustrated Encyclopedia, 04/28/2006 |